Oncoinvent ASA
ONCIN
Rank in Stocks
#27136
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Share Price
$7.23
Last synced: 2026-10-21
Market Cap
$32.40M
Change (1 day)
1.20%
Change (1 year)
6,460.67%
Country
NO
Trade Oncoinvent ASA (ONCIN)
Category
Healthcare
Stock price history for Oncoinvent ASA (ONCIN)
Highest end of day price: $9.10 on 2026-09-01
Lowest end of day price: $27.86 on 2017-12-01
Lowest end of day price: $27.86 on 2017-12-01
Stock price history of Oncoinvent ASA from 2017 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 268.35% |
| 2025 | 32.73% |
| 2024 | -64.40% |
| 2023 | -90.91% |
| 2022 | 4.70% |
| 2021 | -41.35% |
| 2020 | 114.55% |
| 2019 | -57.70% |
| 2018 | 64.64% |
| 2017 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.95 | -3.70% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
